A detailed history of Citigroup Inc transactions in Biogen Inc. stock. As of the latest transaction made, Citigroup Inc holds 238,148 shares of BIIB stock, worth $35.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
238,148
Previous 223,347 6.63%
Holding current value
$35.5 Million
Previous $51.8 Million 10.84%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$189.07 - $236.8 $2.8 Million - $3.5 Million
14,801 Added 6.63%
238,148 $46.2 Million
Q2 2024

Aug 12, 2024

BUY
$190.52 - $236.72 $882,107 - $1.1 Million
4,630 Added 2.12%
223,347 $51.8 Million
Q1 2024

May 10, 2024

SELL
$212.02 - $267.71 $410,470 - $518,286
-1,936 Reduced 0.88%
218,717 $47.2 Million
Q4 2023

Feb 09, 2024

SELL
$222.59 - $267.94 $245,961 - $296,073
-1,105 Reduced 0.5%
220,653 $57.1 Million
Q3 2023

Nov 09, 2023

SELL
$253.3 - $285.89 $3.33 Million - $3.76 Million
-13,144 Reduced 5.6%
221,758 $57 Million
Q2 2023

Aug 10, 2023

BUY
$275.25 - $318.06 $1.36 Million - $1.57 Million
4,936 Added 2.15%
234,902 $66.9 Million
Q1 2023

May 11, 2023

BUY
$256.56 - $292.34 $8.5 Million - $9.69 Million
33,140 Added 16.84%
229,966 $63.9 Million
Q4 2022

Feb 09, 2023

SELL
$252.44 - $306.72 $14.7 Million - $17.9 Million
-58,384 Reduced 22.88%
196,826 $54.5 Million
Q3 2022

Nov 10, 2022

BUY
$194.69 - $268.46 $13.4 Million - $18.5 Million
68,887 Added 36.97%
255,210 $68.1 Million
Q2 2022

Aug 10, 2022

SELL
$187.54 - $223.02 $3.65 Million - $4.34 Million
-19,455 Reduced 9.45%
186,323 $38 Million
Q1 2022

May 12, 2022

SELL
$193.77 - $244.14 $34.3 Million - $43.2 Million
-176,956 Reduced 46.23%
205,778 $43.3 Million
Q4 2021

Feb 10, 2022

BUY
$223.92 - $287.77 $25.1 Million - $32.2 Million
112,061 Added 41.4%
382,734 $91.8 Million
Q3 2021

Nov 10, 2021

BUY
$282.99 - $369.05 $76.6 Million - $99.9 Million
270,673 New
270,673 $76.6 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.